Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; Deposit of Biological Materials, 71304-71306 [2022-25364]
Download as PDF
khammond on DSKJM1Z7X2PROD with NOTICES
71304
Federal Register / Vol. 87, No. 224 / Tuesday, November 22, 2022 / Notices
Quakenbush), has applied for an
amendment to Scientific Research
Permit No. 24334.
DATES: Written, telefaxed, or email
comments must be received on or before
December 22, 2022.
ADDRESSES: The application and related
documents are available for review by
selecting ‘‘Records Open for Public
Comment’’ from the ‘‘Features’’ box on
the Applications and Permits for
Protected Species (APPS) home page,
https://apps.nmfs.noaa.gov, and then
selecting File No. 24334 mod 1 from the
list of available applications. These
documents are also available upon
written request via email to
NMFS.Pr1Comments@noaa.gov.
Written comments on this application
should be submitted via email to
NMFS.Pr1Comments@noaa.gov. Please
include File No. 24334 in the subject
line of the email comment.
Those individuals requesting a public
hearing should submit a written request
via email to NMFS.Pr1Comments@
noaa.gov. The request should set forth
the specific reasons why a hearing on
this application would be appropriate.
FOR FURTHER INFORMATION CONTACT:
Amy Hapeman or Sara Young, (301)
427–8401.
SUPPLEMENTARY INFORMATION: The
subject amendment to Permit No. 24334
is requested under the authority of the
Marine Mammal Protection Act of 1972,
as amended (16 U.S.C. 1361 et seq.), the
regulations governing the taking and
importing of marine mammals (50 CFR
part 216), the Endangered Species Act of
1973, as amended (16 U.S.C. 1531 et
seq.), and the regulations governing the
taking, importing, and exporting of
endangered and threatened species (50
CFR parts 222–226).
Permit No. 24334, issued on July 13,
2021 (86 FR 43630, August 10, 2021),
authorizes the permit holder to conduct
research on five whale species in the
Bering, Chukchi, and Beaufort seas (U.S.
and international waters) adjacent to
Alaska. Researchers may conduct vessel
surveys for tagging (invasive tags or
suction cup tags), biopsy sampling,
photo-identification, and unmanned
aircraft system (UAS) surveys for all
species. Researchers also may conduct
manned aerial surveys and captures for
tagging with biological sample
collection of four beluga whale
(Delphinapterus leucas) stocks and
export and import of skin and blubber
for the target species. Non-target seals
and beluga whales may be
unintentionally harassed, and seals may
be incidentally captured during research
activities. Up to three unintentional
VerDate Sep<11>2014
17:48 Nov 21, 2022
Jkt 259001
beluga mortalities may occur during
captures over the duration of the permit.
The permit holder is requesting the
permit be amended to authorize the
annual receipt, collection, import, or
export of parts from up to 300 beluga
whales and up to 50 other unidentified
cetaceans (any species). Sources of
foreign and domestic samples may
include subsistence harvests, captive
animals, other authorized researchers or
curated collections, bycatch from legal
commercial fishing operations,
cetaceans killed by killer whales, parts
that are sloughed, excreted or
discharged naturally by living
cetaceans, and foreign stranded animals.
No take or harassment of live animals
would be authorized. The amendment
would be valid for the duration of the
permit, which is set to expire on April
30, 2026.
In compliance with the National
Environmental Policy Act of 1969 (42
U.S.C. 4321 et seq.), an initial
determination has been made that the
activity proposed is categorically
excluded from the requirement to
prepare an environmental assessment or
environmental impact statement.
Concurrent with the publication of
this notice in the Federal Register,
NMFS is forwarding copies of this
application to the Marine Mammal
Commission and its Committee of
Scientific Advisors.
Julia M. Harrison,
Chief, Permits and Conservation Division,
Office of Protected Resources, National
Marine Fisheries Service.
[FR Doc. 2022–25430 Filed 11–21–22; 8:45 am]
BILLING CODE 3510–22–P
DEPARTMENT OF COMMERCE
United States Patent and Trademark
Office
Agency Information Collection
Activities; Submission to the Office of
Management and Budget (OMB) for
Review and Approval; Comment
Request; Deposit of Biological
Materials
United States Patent and
Trademark Office, Department of
Commerce.
ACTION: Notice of information collection;
request for comment.
AGENCY:
The United States Patent and
Trademark Office (USPTO), as required
by the Paperwork Reduction Act of
1995, invites comments on the
extension and revision of an existing
information collection: 0651–0022
Deposit of Biological Materials. The
SUMMARY:
PO 00000
Frm 00015
Fmt 4703
Sfmt 4703
purpose of this notice is to allow 60
days for public comment preceding
submission of the information collection
to OMB.
DATES: To ensure consideration,
comments regarding this information
collection must be received on or
January 23, 2023.
ADDRESSES: Interested persons are
invited to submit written comments by
any of the following methods. Do not
submit Confidential Business
Information or otherwise sensitive or
protected information.
• Email: InformationCollection@
uspto.gov. Include ‘‘0651–0022
comment’’ in the subject line of the
message.
• Federal Rulemaking Portal: https://
www.regulations.gov.
• Mail: Justin Isaac, Office of the
Chief Administrative Officer, United
States Patent and Trademark Office,
P.O. Box 1450, Alexandria, VA 22313–
1450.
FOR FURTHER INFORMATION CONTACT:
Requests for additional information
should be directed to Parikha Mehta,
Senior Legal Advisor, United States
Patent and Trademark Office, P.O. Box
1450, Alexandria, VA 22313–1450; by
telephone at 571–272–3248; or by email
at parikha.mehta@uspto.gov with
‘‘0651–0022 comment’’ in the subject
line. Additional information about this
information collection is also available
at https://www.reginfo.gov under
‘‘Information Collection Review.’’
SUPPLEMENTARY INFORMATION:
I. Abstract
This collection covers information
from patent applicants who seek to
deposit biological materials as part of a
patent application according to 37 CFR
1.801–1.809. The information collected
from such patent applicants consists of
information and documentation
demonstrating the applicant’s
compliance with regulatory
requirements, as well as information
regarding the biological sample after it
is deposited. This collection also covers
applications from institutions that wish
to be recognized by the USPTO as a
suitable depository to receive deposits
for patent application purposes. The
information collection requirements for
these actions are separate, as further
discussed below.
A. Deposits of Biological Materials
The deposit of biological materials as
part of a patent application is
authorized by 35 U.S.C. 2(b)(2). The
term ‘‘biological material’’ is defined in
37 CFR 1.801 as including material that
is capable of self-replication, either
E:\FR\FM\22NON1.SGM
22NON1
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 87, No. 224 / Tuesday, November 22, 2022 / Notices
directly or indirectly. When an
invention involves a biological material,
words and figures may not sufficiently
describe how to make and use the
invention in a reproducible manner as
required by 35 U.S.C. 112. In such cases,
the inventive biological material must
be known and readily available to the
public or can be made or isolated
without undue experimentation (see 37
CFR 1.802). In order to satisfy the
‘‘known and readily available’’
requirement, the biological material may
be deposited in a suitable depository
that has been recognized as an
International Depositary Authority
(IDA) established under the Budapest
Treaty per 37 CFR 1.803(a)(1), or any
other depository recognized to be
suitable by the USPTO per 37 CFR
1.803(a)(2). Under the authority of 35
U.S.C. 2(b)(2), the deposit rules (37 CFR
1.801–1.809) set forth examining
procedures and conditions of deposit
which must be satisfied in the event a
deposit is required.
In cases where a deposit of biological
material that is capable of selfreplication either directly or indirectly
is made, and the deposit is not made
under the Budapest Treaty, the USPTO
collects information to determine
whether the deposit meets the viability
requirements of 37 CFR 1.807. This
information includes a viability
statement under 37 CFR 1.807, such
statement identifying:
(1) The name and address of the
depository where the deposit was made,
(2) The name and address of the
depositor,
(3) The date of the deposit,
(4) The identity of the deposit and the
accession number given by the
depository,
(5) The date of the viability test,
(6) The procedures used to obtain a
sample if the test was not done by the
depository, and
(7) A statement that the deposit is
capable of reproduction.
A viability statement is not required
when a deposit is made and accepted
under the Budapest Treaty.
This collection also covers additional
information that may be gathered by the
USPTO after a biological material is
deposited into the recognized
depository. For example, depositors
may be required to submit verification
statements for biological materials
deposited after the effective filing date
of a patent application or written
VerDate Sep<11>2014
17:48 Nov 21, 2022
Jkt 259001
notification that an acceptable deposit
will be made. Occasionally a deposit
may be lost, contaminated, or is not able
to self-replicate, and a replacement or
supplemental deposit needs to be made.
This information collection includes a
required written notification that the
depositor must submit to the USPTO
disclosing the particulars of such
situation and request a certificate of
correction by the USPTO authorizing a
replacement or supplemental deposit.
There are no forms associated with
the information collected by the USPTO
in connection with the deposit of
biological materials, however there are
forms available under the Budapest
Treaty for use with international
depositories.
B. Depositories
Institutions that wish to be recognized
by the USPTO as a suitable depository
to receive deposits for patent purposes,
are required by 37 CFR 1.803(b) to make
a request demonstrating that they are
qualified to store and test the biological
materials submitted to them under
patent applications (see also MPEP
2405). This collection covers the
information that a depository must
submit to the USPTO when seeking
recognition by the Office as a suitable
depository under 37 CFR 1.803(a)(2).
This information enables the USPTO to
evaluate whether such a depository has
internal practices (both technical and
administrative) and the technical ability
sufficient to protect the integrity of the
biological materials being stored by U.S.
patent applicants. This information
includes:
(1) The name and address of the depository
seeking recognition under 37 CFR 1.803(a)(2),
(2) Detailed information as to the capacity
of the depository to comply with the
requirements of 37 CFR 1.803(a)(2), including
information on its legal status, scientific
standing, staff, and facilities;
(3) An indication that the depository
intends to be available, for the purposes of
deposit, to any depositor under these same
conditions;
(4) Where the depository intends to accept
for deposit only certain kinds of biological
material, specify such kinds; and
(5) An indication of the amount of any fees
that the depository will, upon acquiring the
status of suitable depository under paragraph
(a)(2) of this section, charge for storage,
viability statements and furnishings of
samples of the deposit.
This collection also includes
additional information gathered by the
PO 00000
Frm 00016
Fmt 4703
Sfmt 4703
71305
USPTO that may be needed after a
depository has been recognized by the
USPTO under 37 CFR 1.803(a)(2), such
as requests to handle additional types of
biological materials other than the
material originally recognized, and
viability statements that depositories
may submit on behalf of depositors for
deposits tested at the depository and/or
documentation proving the public has
been notified about where to obtain
samples. There is no application form
associated with requests under 37 CFR
1.803(b) to become a recognized
depository.
II. Method of Collection
Electronically via the USPTO’s patent
electronic filing system, by mail or hand
delivery to the USPTO.
III. Data
OMB Control Number: 0651–0022.
Forms: No form associated for
domestic depositories; Forms BP/1, BP/
2, BP/3, BP/9 for use of international
depositories under the Budapest Treaty.
• BP/1 (Statement in the Case of an
Original Deposit (Rule 6.1))
• BP/2 (Statement in the Case of a New
Deposit with the Same International
Depositary Authority (Rule 6.2))
• BP/3 (Statement in the Case of a New
Deposit with Another International
Depositary Authority (Rule 6.2))
• BP/9 (Viability Statement (Rule 10.2)
(International Form))
Type of Review: Extension and
revision of a currently approved
information collection.
Affected Public: Private sector.
Respondent’s Obligation: Required to
obtain or retain benefits.
Estimated Number of Annual
Respondents: 3,301 respondents.
Estimated Number of Annual
Responses: 3,301 responses.
Estimated Time per Response: The
USPTO estimates that the responses in
this information collection will take the
public approximately between 1 hour
and 5 hours to complete, depending on
the complexity of the situation and
item, to gather the necessary
information, prepare the appropriate
document(s), and submit the
information to the USPTO.
Estimated Total Annual Respondent
Burden Hours: 3,305 hours.
Estimated Total Annual Respondent
Hourly Cost Burden: $475,788.
E:\FR\FM\22NON1.SGM
22NON1
71306
Federal Register / Vol. 87, No. 224 / Tuesday, November 22, 2022 / Notices
TABLE 1—TOTAL BURDEN HOURS AND HOURLY COSTS TO PRIVATE SECTOR RESPONDENTS
Item
No.
1 .......
2 .......
Item
Estimated
annual
respondents
Responses per
respondent
Estimated
annual
responses
Estimated
time per
response
(hours)
Estimated
burden
(hour/year)
Rate 1
($/hour)
Estimated
annual
respondent
cost burden
(a)
(b)
(a) × (b) = (c)
(d)
(c) × (d) = (e)
(f)
(e) × (f) = (g)
Deposited Materials ...................
Request for Depository Approval
3,300
1
1
1
3,300
1
1 .................
5 .................
3,300
5
$143.96
143.96
$475,068
720
Totals ..................................
3,301
..........................
3,301
....................
3,305
........................
475,788
1 Bureau
of Labor Statistic rate for attorneys in scientific research and development services (23–1011—Lawyers), plus 30% added for benefits and overhead
(https://www.bls.gov/oes/current/oes231011.htm).
Estimated Total Annual Respondent
Non-hourly Cost Burden: $9,259,809.
There are no maintenance costs, record
keeping costs, or filing fees associated
with this information collection.
However, the USPTO estimates that the
total annual (non-hour) cost burden for
this information collection, in the form
of capital start-up costs ($8,250,000) and
postage ($1,009,809) is $9,259,809.
khammond on DSKJM1Z7X2PROD with NOTICES
Captial Start-Up Costs
Depositories charge fees to depositors;
all depositories charge about the same
rates for their services. For example, the
American Type Culture Collection
(ATCC), one of the world’s leading
biological supply houses and recognized
patent depositories, offers
comprehensive patent services for
$2,500 per deposit. Any deposits from
outside the US may have additional
requirements, from other Federal
Agencies, as a part of their importation
process. The USPTO estimates that the
total non-hour respondent cost burden
in the form of capital start-up costs
amounts to $8,250,000 (3,300
respondents × $2,500).
Postage
Biological deposits are generally
shipped to the depository ‘‘Domestic
Overnight’’ by Federal Express (FedEx)
and, since depositors are urged to
supply frozen or freeze-dried material, it
must be packed in dry ice. Dry ice itself
is considered dangerous goods and
requires special packaging. Additional
FedEx special handling charges for
inaccessible dangerous goods shipments
of $40 per shipment apply for
temperature-sensitive biological
materials and also for the dry ice. An
average cost for shipping by FedEx
‘‘Domestic Overnight’’ is estimated to be
$90. If the shipment requires a pick-up
by FedEx, there is an additional charge
of $6. Special packaging is also required
for these shipments. The average cost of
frozen infectious shippers is estimated
to be $170 per package of four for
specimen shipments requiring
refrigeration or dry ice. Therefore, the
USPTO estimates the total postage costs
VerDate Sep<11>2014
17:48 Nov 21, 2022
Jkt 259001
average $306 per shipment, for a cost to
respondents of $1,009,800 (3,300
respondents × $306).
The USPTO estimates that it will
receive from depositorites 1 request for
recognition. The USPTO estimates that
the postage cost for a mailed submission
of a request for recognition from a
depository using a Priority Mail 2-day
flat rate legal envelope is $9.25.
Therefore, the USPTO estimates that the
total mailing costs for this information
collection is $9.00 per year.
IV. Request for Comments
The USPTO is soliciting public
comments to:
(a) Evaluate whether the collection of
information is necessary for the proper
performance of the functions of the
Agency, including whether the
information will have practical utility;
(b) Evaluate the accuracy of the
Agency’s estimate of the burden of the
collection of information, including the
validity of the methodology and
assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected; and
(d) Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses.
All comments submitted in response
to this notice are a matter of public
record. USPTO will include or
summarize each comment in the request
to OMB to approve this information
collection. Before including an address,
phone number, email address, or other
personally identifiable information (PII)
in a comment, be aware that the entire
comment—including PII—may be made
publicly available at any time. While
you may ask in your comment to
withhold PII from public view, USPTO
PO 00000
Frm 00017
Fmt 4703
Sfmt 4703
cannot guarantee that it will be able to
do so.
Justin Isaac,
Information Collections Officer, Office of the
Chief Administrative Officer, United States
Patent and Trademark Office.
[FR Doc. 2022–25364 Filed 11–21–22; 8:45 am]
BILLING CODE 3510–16–P
DEPARTMENT OF COMMERCE
Patent and Trademark Office
Agency Information Collection
Activities; Submission to the Office of
Management and Budget (OMB) for
Review and Approval; Comment
Request; Legal Processes
The United States Patent and
Trademark Office (USPTO) will submit
the following information collection
request to the Office of Management and
Budget (OMB) for review and clearance
in accordance with the Paperwork
Reduction Act of 1995, on or after the
date of publication of this notice. The
USPTO invites comment on this
information collection renewal, which
helps the USPTO assess the impact of
its information collection requirements
and minimize the public’s reporting
burden. Public comments were
previously requested via the Federal
Register on September 16, 2022 during
a 60-day comment period. This notice
allows for an additional 30 days for
public comments.
Agency: United States Patent and
Trademark Office, Department of
Commerce.
Title: Legal Processes.
OMB Control Number: 0651–0046.
Needs and Uses: This collection
covers information requirements related
to civil actions and claims involving
current and former employees of the
United States Patent and Trademark
Office (USPTO). The rules for these
legal processes may be found under 37
CFR part 104, which outlines
procedures for service of process,
demands for employee testimony and
production of documents in legal
E:\FR\FM\22NON1.SGM
22NON1
Agencies
[Federal Register Volume 87, Number 224 (Tuesday, November 22, 2022)]
[Notices]
[Pages 71304-71306]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-25364]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Agency Information Collection Activities; Submission to the
Office of Management and Budget (OMB) for Review and Approval; Comment
Request; Deposit of Biological Materials
AGENCY: United States Patent and Trademark Office, Department of
Commerce.
ACTION: Notice of information collection; request for comment.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office (USPTO), as
required by the Paperwork Reduction Act of 1995, invites comments on
the extension and revision of an existing information collection: 0651-
0022 Deposit of Biological Materials. The purpose of this notice is to
allow 60 days for public comment preceding submission of the
information collection to OMB.
DATES: To ensure consideration, comments regarding this information
collection must be received on or January 23, 2023.
ADDRESSES: Interested persons are invited to submit written comments by
any of the following methods. Do not submit Confidential Business
Information or otherwise sensitive or protected information.
Email: [email protected]. Include ``0651-
0022 comment'' in the subject line of the message.
Federal Rulemaking Portal: https://www.regulations.gov.
Mail: Justin Isaac, Office of the Chief Administrative
Officer, United States Patent and Trademark Office, P.O. Box 1450,
Alexandria, VA 22313-1450.
FOR FURTHER INFORMATION CONTACT: Requests for additional information
should be directed to Parikha Mehta, Senior Legal Advisor, United
States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA
22313-1450; by telephone at 571-272-3248; or by email at
[email protected] with ``0651-0022 comment'' in the subject line.
Additional information about this information collection is also
available at https://www.reginfo.gov under ``Information Collection
Review.''
SUPPLEMENTARY INFORMATION:
I. Abstract
This collection covers information from patent applicants who seek
to deposit biological materials as part of a patent application
according to 37 CFR 1.801-1.809. The information collected from such
patent applicants consists of information and documentation
demonstrating the applicant's compliance with regulatory requirements,
as well as information regarding the biological sample after it is
deposited. This collection also covers applications from institutions
that wish to be recognized by the USPTO as a suitable depository to
receive deposits for patent application purposes. The information
collection requirements for these actions are separate, as further
discussed below.
A. Deposits of Biological Materials
The deposit of biological materials as part of a patent application
is authorized by 35 U.S.C. 2(b)(2). The term ``biological material'' is
defined in 37 CFR 1.801 as including material that is capable of self-
replication, either
[[Page 71305]]
directly or indirectly. When an invention involves a biological
material, words and figures may not sufficiently describe how to make
and use the invention in a reproducible manner as required by 35 U.S.C.
112. In such cases, the inventive biological material must be known and
readily available to the public or can be made or isolated without
undue experimentation (see 37 CFR 1.802). In order to satisfy the
``known and readily available'' requirement, the biological material
may be deposited in a suitable depository that has been recognized as
an International Depositary Authority (IDA) established under the
Budapest Treaty per 37 CFR 1.803(a)(1), or any other depository
recognized to be suitable by the USPTO per 37 CFR 1.803(a)(2). Under
the authority of 35 U.S.C. 2(b)(2), the deposit rules (37 CFR 1.801-
1.809) set forth examining procedures and conditions of deposit which
must be satisfied in the event a deposit is required.
In cases where a deposit of biological material that is capable of
self-replication either directly or indirectly is made, and the deposit
is not made under the Budapest Treaty, the USPTO collects information
to determine whether the deposit meets the viability requirements of 37
CFR 1.807. This information includes a viability statement under 37 CFR
1.807, such statement identifying:
(1) The name and address of the depository where the deposit was
made,
(2) The name and address of the depositor,
(3) The date of the deposit,
(4) The identity of the deposit and the accession number given by
the depository,
(5) The date of the viability test,
(6) The procedures used to obtain a sample if the test was not done
by the depository, and
(7) A statement that the deposit is capable of reproduction.
A viability statement is not required when a deposit is made and
accepted under the Budapest Treaty.
This collection also covers additional information that may be
gathered by the USPTO after a biological material is deposited into the
recognized depository. For example, depositors may be required to
submit verification statements for biological materials deposited after
the effective filing date of a patent application or written
notification that an acceptable deposit will be made. Occasionally a
deposit may be lost, contaminated, or is not able to self-replicate,
and a replacement or supplemental deposit needs to be made. This
information collection includes a required written notification that
the depositor must submit to the USPTO disclosing the particulars of
such situation and request a certificate of correction by the USPTO
authorizing a replacement or supplemental deposit.
There are no forms associated with the information collected by the
USPTO in connection with the deposit of biological materials, however
there are forms available under the Budapest Treaty for use with
international depositories.
B. Depositories
Institutions that wish to be recognized by the USPTO as a suitable
depository to receive deposits for patent purposes, are required by 37
CFR 1.803(b) to make a request demonstrating that they are qualified to
store and test the biological materials submitted to them under patent
applications (see also MPEP 2405). This collection covers the
information that a depository must submit to the USPTO when seeking
recognition by the Office as a suitable depository under 37 CFR
1.803(a)(2). This information enables the USPTO to evaluate whether
such a depository has internal practices (both technical and
administrative) and the technical ability sufficient to protect the
integrity of the biological materials being stored by U.S. patent
applicants. This information includes:
(1) The name and address of the depository seeking recognition
under 37 CFR 1.803(a)(2),
(2) Detailed information as to the capacity of the depository to
comply with the requirements of 37 CFR 1.803(a)(2), including
information on its legal status, scientific standing, staff, and
facilities;
(3) An indication that the depository intends to be available,
for the purposes of deposit, to any depositor under these same
conditions;
(4) Where the depository intends to accept for deposit only
certain kinds of biological material, specify such kinds; and
(5) An indication of the amount of any fees that the depository
will, upon acquiring the status of suitable depository under
paragraph (a)(2) of this section, charge for storage, viability
statements and furnishings of samples of the deposit.
This collection also includes additional information gathered by
the USPTO that may be needed after a depository has been recognized by
the USPTO under 37 CFR 1.803(a)(2), such as requests to handle
additional types of biological materials other than the material
originally recognized, and viability statements that depositories may
submit on behalf of depositors for deposits tested at the depository
and/or documentation proving the public has been notified about where
to obtain samples. There is no application form associated with
requests under 37 CFR 1.803(b) to become a recognized depository.
II. Method of Collection
Electronically via the USPTO's patent electronic filing system, by
mail or hand delivery to the USPTO.
III. Data
OMB Control Number: 0651-0022.
Forms: No form associated for domestic depositories; Forms BP/1,
BP/2, BP/3, BP/9 for use of international depositories under the
Budapest Treaty.
BP/1 (Statement in the Case of an Original Deposit (Rule 6.1))
BP/2 (Statement in the Case of a New Deposit with the Same
International Depositary Authority (Rule 6.2))
BP/3 (Statement in the Case of a New Deposit with Another
International Depositary Authority (Rule 6.2))
BP/9 (Viability Statement (Rule 10.2) (International Form))
Type of Review: Extension and revision of a currently approved
information collection.
Affected Public: Private sector.
Respondent's Obligation: Required to obtain or retain benefits.
Estimated Number of Annual Respondents: 3,301 respondents.
Estimated Number of Annual Responses: 3,301 responses.
Estimated Time per Response: The USPTO estimates that the responses
in this information collection will take the public approximately
between 1 hour and 5 hours to complete, depending on the complexity of
the situation and item, to gather the necessary information, prepare
the appropriate document(s), and submit the information to the USPTO.
Estimated Total Annual Respondent Burden Hours: 3,305 hours.
Estimated Total Annual Respondent Hourly Cost Burden: $475,788.
[[Page 71306]]
Table 1--Total Burden Hours and Hourly Costs to Private Sector Respondents
--------------------------------------------------------------------------------------------------------------------------------------------------------
Estimated
Estimated Responses per Estimated annual Estimated time Estimated Rate \1\ ($/ annual
Item No. Item annual respondent responses per response burden (hour/ hour) respondent
respondents (hours) year) cost burden
(a) (b) (a) x (b) = (c) (d).............. (c) x (d) = (f) (e) x (f) =
(e) (g)
--------------------------------------------------------------------------------------------------------------------------------------------------------
1.......... Deposited Materials. 3,300 1 3,300 1................ 3,300 $143.96 $475,068
2.......... Request for 1 1 1 5................ 5 143.96 720
Depository Approval.
----------------------------------------------------------------------------------------------------------------------
Totals........... 3,301 ............... 3,301 ................. 3,305 .............. 475,788
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ Bureau of Labor Statistic rate for attorneys in scientific research and development services (23-1011--Lawyers), plus 30% added for benefits and
overhead (https://www.bls.gov/oes/current/oes231011.htm).
Estimated Total Annual Respondent Non-hourly Cost Burden:
$9,259,809. There are no maintenance costs, record keeping costs, or
filing fees associated with this information collection. However, the
USPTO estimates that the total annual (non-hour) cost burden for this
information collection, in the form of capital start-up costs
($8,250,000) and postage ($1,009,809) is $9,259,809.
Captial Start-Up Costs
Depositories charge fees to depositors; all depositories charge
about the same rates for their services. For example, the American Type
Culture Collection (ATCC), one of the world's leading biological supply
houses and recognized patent depositories, offers comprehensive patent
services for $2,500 per deposit. Any deposits from outside the US may
have additional requirements, from other Federal Agencies, as a part of
their importation process. The USPTO estimates that the total non-hour
respondent cost burden in the form of capital start-up costs amounts to
$8,250,000 (3,300 respondents x $2,500).
Postage
Biological deposits are generally shipped to the depository
``Domestic Overnight'' by Federal Express (FedEx) and, since depositors
are urged to supply frozen or freeze-dried material, it must be packed
in dry ice. Dry ice itself is considered dangerous goods and requires
special packaging. Additional FedEx special handling charges for
inaccessible dangerous goods shipments of $40 per shipment apply for
temperature-sensitive biological materials and also for the dry ice. An
average cost for shipping by FedEx ``Domestic Overnight'' is estimated
to be $90. If the shipment requires a pick-up by FedEx, there is an
additional charge of $6. Special packaging is also required for these
shipments. The average cost of frozen infectious shippers is estimated
to be $170 per package of four for specimen shipments requiring
refrigeration or dry ice. Therefore, the USPTO estimates the total
postage costs average $306 per shipment, for a cost to respondents of
$1,009,800 (3,300 respondents x $306).
The USPTO estimates that it will receive from depositorites 1
request for recognition. The USPTO estimates that the postage cost for
a mailed submission of a request for recognition from a depository
using a Priority Mail 2-day flat rate legal envelope is $9.25.
Therefore, the USPTO estimates that the total mailing costs for this
information collection is $9.00 per year.
IV. Request for Comments
The USPTO is soliciting public comments to:
(a) Evaluate whether the collection of information is necessary for
the proper performance of the functions of the Agency, including
whether the information will have practical utility;
(b) Evaluate the accuracy of the Agency's estimate of the burden of
the collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected; and
(d) Minimize the burden of the collection of information on those
who are to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submission of responses.
All comments submitted in response to this notice are a matter of
public record. USPTO will include or summarize each comment in the
request to OMB to approve this information collection. Before including
an address, phone number, email address, or other personally
identifiable information (PII) in a comment, be aware that the entire
comment--including PII--may be made publicly available at any time.
While you may ask in your comment to withhold PII from public view,
USPTO cannot guarantee that it will be able to do so.
Justin Isaac,
Information Collections Officer, Office of the Chief Administrative
Officer, United States Patent and Trademark Office.
[FR Doc. 2022-25364 Filed 11-21-22; 8:45 am]
BILLING CODE 3510-16-P